antibody

CD45 Polyclonal Antibody

MBS448023

0.6 mg

285 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog

Antibody

CD45 Polyclonal Antibody

[CD45]

[Anti-CD45; B220; CD45 antigen; CD45R; GP180; L-CA; LCA; leukocyte common antigen; LY5; protein tyrosine phosphatase; PTPRC; receptor type c polypeptide; receptor-type tyrosine-protein phosphatase C; RP11-553K8.4; T200; T200 glycoprotein; T200 leukocyte common antigen antibody]

[CD45; Receptor-type tyrosine-protein phosphatase C; receptor-type tyrosine-protein phosphatase C; CD45 antigen; T200 glycoprotein; T200 leukocyte common antigen; protein tyrosine phosphatase, receptor type, c polypeptide; protein tyrosine phosphatase, receptor type, C; Leukocyte common antigen; L-CA; T200]

[CD45]

[PTPRC; PTPRC; LCA; LY5; B220; CD45; L-CA; T200; CD45R; GP180; CD45; L-CA]

PTPRC_HUMAN

Polyclonal

IgG

Goat

Reacts against Human, Rat, Mouse, Canine, and Monkey proteins

72

Using Jurkat cell lysate detects a band 180-220 kDa by Western blot.

Polyclonal antibody supplied as (3 mg/ml) aliquot in PBS, 20% glycerol and 0.05% sodium azide. This antibody is epitope-affinity purified from goat antiserum.

Store at -20 degree C for long term storage. Store at 2-8 degree C for up to one month. Avoid freeze/thaw cycles.

Western Blot (WB)

Western Blot: 1:500-1:2,000

Reactivity Chart

Testing Data

Immunogen: Purified recombinant peptide derived from within residues 1,260 aa to the C-terminus of human CD45 produced in E. coli. Antigen: Purified recombinant peptide derived from within residues 1,260 aa to the C-terminus of human CD45 produced in E. coli.

Handling: The antibody solution should be gently mixed before use.

Protein tyrosine phosphatase, receptor type, C. Goat polyclonal antibody to CD45. It is a 180-220 kDa type I transmembrane glycoprotein and a member of the protein tyrosine phosphatase (PTP) family. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. It is expressed in all hematopoietic cells, but highest on lymphocytes. PTPs are known to be signalling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. It has intrinsic tyrosine phosphatase activity and it is essential for T and B cell antigen receptor-mediated activation. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signalling. CD45 also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signalling. The cross-linking of CD45 induces apoptosis in lymphocytes.

44242008

AAS46946.1

P08575

147,254 Da

Adaptive Immune System Pathway (366160); Axon Guidance Pathway (105688); B Cell Receptor Signaling Pathway (198909); BCR Signaling Pathway (138058); CXCR4-mediated Signaling Events Pathway (137910); Cell Adhesion Molecules (CAMs) Pathway (83069); Cell Adhesion Molecules (CAMs) Pathway (480); Developmental Biology Pathway (477129); EPO Receptor Signaling Pathway (198882); Fc Gamma R-mediated Phagocytosis Pathway (114228)

The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitosis, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus is classified as a receptor type PTP. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jun 2012]

Function: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity . By similarity. Ref.6 Ref.8. Catalytic activity: Protein tyrosine phosphate + H2O = protein tyrosine + phosphate. Subunit structure: Binds GANAB and PRKCSH . By similarity. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Ref.8 Ref.9. Subcellular location: Membrane; Single-pass type I membrane protein. Membrane raft. Note: Colocalized with DPP4 in membrane rafts. Ref.9. Domain: The first PTPase domain interacts with SKAP1. Post-translational modification: Heavily N- and O-glycosylated. Involvement in disease: Severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]: A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.16 Ref.17Multiple sclerosis (MS) [MIM:126200]: A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheath, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease.Note: Disease susceptibility may be associated with variations affecting the gene represented in this entry. Ref.16. Sequence similarities: Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily.Contains 2 fibronectin type-III domains.Contains 2 tyrosine-protein phosphatase domains.

0.6 mg

285 USD

1.5 mg

415